Eli Lilly (LLY) Cost of Revenue (2009 - 2026)

Eli Lilly (LLY) has reported Cost of Revenue for 18 consecutive years, with $3.6 billion the latest figure, recorded in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $3.6 billion, up 60.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 billion (up 38.3% YoY), and the FY2025 annual result was $11.1 billion, up 31.29% from the prior year.
• Cost of Revenue was $3.6 billion for Q1 2026 at Eli Lilly, up from $3.4 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $3.6 billion in Q1 2026 and troughed at $1.4 billion in Q2 2022.
• Average Cost of Revenue over 5 years is $2.2 billion, with a median of $2.1 billion recorded in 2022.
• Year-over-year, Cost of Revenue retreated 26.76% in 2022 and surged 60.76% in 2026.
• Over 5 years, Cost of Revenue stood at $1.5 billion in 2022, then grew by 15.48% to $1.8 billion in 2023, then soared by 34.44% to $2.4 billion in 2024, then jumped by 40.28% to $3.4 billion in 2025, then gained by 6.09% to $3.6 billion in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $3.6 billion in Q1 2026, $3.4 billion in Q4 2025, and $3.0 billion in Q3 2025.